Hepatitis testing uses virus-specific blood tests to look for infection, past exposure, or immunity. The right test depends on the question: hepatitis A IgM helps evaluate suspected recent illness; hepatitis B screening combines three markers; and hepatitis C antibody screening needs RNA testing when reactive to identify current infection.
Ulta Lab Tests helps patients explore testing options and bring results to a healthcare professional. This guide explains test selection and interpretation; it does not replace medical evaluation, diagnosis, or treatment.
Hepatitis means inflammation of the liver. Viruses are one cause; medications, alcohol, autoimmune disease, and other conditions can also injure the liver. A negative A/B/C panel therefore does not explain every abnormal liver result.
| Virus | Typical transmission | Course and prevention |
|---|---|---|
| Hepatitis A (HAV) | Ingestion of virus through fecal contamination, including contaminated food or close personal contact. | Acute illness; no chronic infection. A vaccine is available. |
| Hepatitis B (HBV) | Infected blood, sexual exposure, and transmission around birth. | Acute or chronic infection. A vaccine is available. |
| Hepatitis C (HCV) | Primarily infected blood, including shared injection equipment; transmission around birth and sexual transmission can also occur. | May become chronic. There is no vaccine; effective antiviral treatment is available. |
Hepatitis B and C are not spread through ordinary hugging or sharing a meal. Avoid sharing items that may carry blood, such as razors. The relevant exposure route matters more than assumptions about a person's appearance or lifestyle. CDC: hepatitis A; CDC: hepatitis B; CDC: hepatitis C.
The liver processes nutrients, makes important proteins, and handles substances carried in the blood. Persistent HBV or HCV infection can lead to fibrosis, meaning scar tissue, and sometimes cirrhosis or liver cancer. Infection may be present without noticeable symptoms.
Testing can identify an infection that needs care, show evidence of prior exposure, or help clarify immunity. These are different benefits. For broader interpretation of liver enzymes and liver health, read the Liver Function Tests pillar. For differences among antibodies, antigens, and molecular tests, use the Infectious Disease Testing pillar.
Screening can be appropriate even when you feel well. CDC recommends hepatitis B screening at least once for adults aged 18 and older using the triple panel. Hepatitis C screening is recommended at least once for adults and during each pregnancy, except in settings where current HCV infection prevalence is below 0.1%. Ongoing risks can warrant repeat testing.
Pregnancy also requires HBsAg screening during each pregnancy. A clinician may add the full HBV triple panel if it has not previously been completed. Hepatitis A IgM is used for suspected acute illness rather than routine screening of well adults. CDC HBV screening recommendations; CDC HCV testing guidance; CDC HAV testing guidance.
| Situation | What it may mean | Testing or next step |
|---|---|---|
| Fatigue, nausea, appetite loss, dark urine, or jaundice | Possible liver or other illness; symptoms cannot identify the virus. | Clinical evaluation, selected hepatitis markers, and a Hepatic Function Panel. |
| Needlestick, blood exposure, or known infected contact | Possible recent exposure; early results may be negative. | Prompt exposure assessment with baseline and follow-up tests. |
| Unexplained elevated liver enzymes | Viral and nonviral causes are possible. | History-guided HBV/HCV testing and evaluation of other causes. |
| Planned immune-suppressing treatment | Past HBV infection can reactivate. | Clinician-directed HBV screening and follow-up planning. |
Seek prompt care for new jaundice. Confusion, vomiting blood, severe abdominal pain, fainting, or rapidly worsening illness needs urgent medical evaluation. Do not wait for routine online testing after a significant recent exposure. Prevention after hepatitis A exposure can be time-sensitive, including a two-week window for recommended postexposure measures. CDC HAV exposure guidance.
IgM and total antibodies answer different questions. Hepatitis A IgM supports evaluation of recent infection in someone with compatible illness. Total antibody includes IgM and IgG and cannot date infection by itself.
| Test | What it measures and when it helps | Result meaning and limitation |
|---|---|---|
| Hepatitis A IgM Antibody | IgM antibodies; targeted evaluation of suspected acute HAV. | Reactive results may support recent infection. False reactivity and recent vaccination can complicate interpretation; this is not a routine immunity test. |
| Hepatitis A Antibody, Total | Combined HAV antibodies; selected immunity or prior-exposure questions. | Positive total antibody with negative IgM is consistent with past infection or vaccination. Total antibody alone cannot distinguish acute infection from remote exposure. |
Testing very early can miss infection. Clinicians consider symptoms, exposure dates, vaccination history, and whether repeat testing is needed. Routine testing before hepatitis A vaccination is usually unnecessary. CDC: interpreting hepatitis A tests.
The hepatitis B triple panel combines surface antigen, surface antibody, and total core antibody. An immunity-only test or an acute hepatitis panel is not automatically equivalent. Check the actual components rather than relying on a panel's marketing name.
| Test | What it measures | Interpretation role |
|---|---|---|
| Hepatitis B Surface Antigen Test with Reflex to Confirmation (HBsAg) | A protein associated with HBV. | A confirmed positive result generally indicates current infection. One result does not establish duration; recent vaccination can cause transient reactivity. |
| Hepatitis B Core Antibody, Total (total anti-HBc) | Antibodies to the virus's core. | Usually indicates past or current natural infection. Vaccination alone does not produce this marker. |
| Hepatitis B Surface Antibody, Quantitative (anti-HBs) | The amount of antibody to HBV surface antigen. | Helps assess immunity with vaccination records and the other markers. A numerical titer is not an infection viral load. |
| HBsAg | Total anti-HBc | Anti-HBs | General meaning |
|---|---|---|---|
| Negative | Negative | Negative | May be susceptible; interpret with vaccination records, prior response, and exposure timing. |
| Negative | Negative | Positive | Usually vaccine-associated immunity when the vaccine series is documented. |
| Negative | Positive | Positive | Usually resolved natural infection; reactivation risk may matter with immune suppression. |
| Positive | Positive | Usually negative | Current infection; additional testing and history distinguish acute from chronic infection. |
| Negative | Positive | Negative | Isolated core antibody: several explanations are possible, including remote infection, false positivity, or occult infection. |
These examples do not cover every pattern. Chronic infection is generally established by HBsAg persistence for at least six months or appropriate prior clinical evidence. An isolated core-antibody result needs context rather than an automatic label of immunity or active disease. CDC: HBV result interpretation.
Negative HBeAg does not exclude active viral replication. HBV DNA, liver enzymes, fibrosis assessment, and trends answer complementary questions. For detailed follow-up, read Chronic Hepatitis B Tests: HBV DNA, ALT, Fibrosis, and Monitoring.
Start with an antibody test that automatically adds HCV RNA testing when reactive, unless the clinical situation calls for RNA directly. “Reflex” means the laboratory performs the follow-up test when the initial result meets specified criteria.
| Test | Purpose | Key limitation |
|---|---|---|
| Hepatitis C Antibody Test with Reflex to RNA Quantitative PCR | Screens for antibodies, then checks for viral RNA when reflex criteria are met. | Antibody reactivity alone may reflect current infection, cleared infection, or false positivity. |
| Hepatitis C Viral RNA, Quantitative, Real-Time PCR | Detects and measures viral RNA; used for current-infection assessment, selected recent exposures, and treatment-related follow-up. | A viral-load number does not establish liver injury severity or fibrosis stage. |
| Hepatitis C Viral RNA, Genotype, LiPA | Identifies viral genotype when it affects the treatment plan. | Conditional testing; it is not needed for every person receiving a pangenotypic regimen. |
RNA testing may need repeating after recent exposure, with compatible illness, or if there is a specimen concern. Antibodies can remain positive after cure, so antibody testing cannot document cure or reliably detect reinfection. CDC: HCV testing sequence.
Routine RNA testing during uncomplicated treatment is generally unnecessary. Cure assessment usually uses HCV RNA at least 12 weeks after therapy ends; current guidance also allows a four-week assessment in selected patients. Timing belongs in the treating clinician's plan. Read Chronic Hepatitis C Tests: HCV RNA, Fibrosis, and Confirming Cure for the full pathway. AASLD/IDSA monitoring guidance.
A negative result soon after exposure can fall within a window period. HCV RNA often becomes detectable about one to two weeks after exposure; HCV antibodies commonly take eight to eleven weeks. Neither interval is a guarantee for an individual patient.
HAV IgM typically becomes detectable near symptom onset, while HBV markers appear at different times. There is no single “test on this day” rule that safely covers all three viruses. Record the exposure date and ask which baseline and repeat tests match that exposure. For suspected HCV exposure within the previous six months, RNA testing can be appropriate despite a negative antibody result. CDC HCV timing guidance; CDC HAV timing guidance.
Virus tests identify infection-related markers; liver tests assess different consequences or competing explanations. They should not be treated as interchangeable.
| Test | Information it adds | Important limitation |
|---|---|---|
| Hepatic Function Panel | Liver enzymes, bilirubin, and proteins provide injury, bile-flow, and functional context. Elevated ALT/AST can suggest cell injury; bilirubin and albumin answer other questions. | Abnormal values have multiple causes. Normal enzymes do not rule out fibrosis; the panel does not identify a hepatitis virus. |
| Complete Blood Count with Differential and Platelets | Blood-cell counts and platelets can inform a broader assessment. | Low platelets may have many causes and do not establish cirrhosis. |
| Prothrombin Time with INR | Clotting-time information can help assess liver synthetic function in selected settings. | Anticoagulants, vitamin K status, and other conditions can affect results. |
Fibrosis assessment may involve blood-based scores and elastography, which measures liver stiffness. A viral load cannot substitute for that assessment. A score estimates risk rather than proving a fibrosis stage. See how liver enzymes, function, and fibrosis findings fit together. MedlinePlus: liver function tests; AASLD/IDSA: HCV evaluation.
A larger panel is not automatically better. Compare components with recent results to avoid repeating tests unnecessarily. The Complete Guide to Lab Tests and Blood Work explains how individual tests and panels serve different purposes.
Hepatitis antibody and viral tests usually do not require fasting, but another test in the same order may. Follow the specific collection instructions. Bring required identification and the laboratory order, and tell your care team about recent vaccination, exposure dates, prior hepatitis treatment, medicines, and supplements. Do not stop prescribed medication on your own.
“Reactive” and “nonreactive” describe qualitative results. Quantitative tests supply a number, units, and assay limits. “Detected below the quantification limit” is different from “not detected.” Neither a flag nor a reference interval supplies the full clinical answer.
For example, an anti-HBs level of at least 10 mIU/mL measured one to two months after a completed vaccine series can document a protective response. Antibodies may decline later while immune protection persists. An old vaccination history therefore matters when interpreting a low titer. CDC HBV guidance.
Keep complete reports and compare dates, units, methods, and comments. Read How to Read and Understand Your Lab Results for help preparing a focused follow-up conversation.
Ulta Lab Tests offers online access to laboratory testing where available. Review the test purpose, included components, preparation instructions, collection options, and displayed costs before ordering. Arrange professional interpretation and a follow-up plan, especially after a reactive screening result.
The Direct-Access Lab Testing cornerstone guide explains ordering, collection, results access, payment considerations, and coordination with healthcare. Direct-access testing is not an emergency service.
No. A hepatitis panel looks for selected viral markers, while a liver panel measures substances such as enzymes, bilirubin, and proteins. Panel contents vary. Check the named components: an acute hepatitis panel may omit the surface antibody and total core antibody needed for a complete initial HBV screening assessment.
Yes. Liver enzyme results can be normal even when HBV or HCV infection is present. Enzymes reflect a different aspect of health from viral markers, and they do not reliably exclude liver scarring. Screening should follow the person's history and applicable recommendations, rather than depend only on an abnormal liver panel.
No. The meaning depends on the specific antibody. Some HAV or HBV antibody patterns are consistent with immunity or past infection. HCV antibody can remain detectable after infection clears. Read the exact test name and its companion results before drawing conclusions; the word “positive” alone is insufficient.
No. Hepatitis A causes acute infection and does not become chronic hepatitis. Symptoms can sometimes persist or recur during recovery, but that is different from chronic HBV or HCV infection. New or worsening symptoms deserve medical follow-up rather than an assumption that they are an expected part of recovery.
No. A positive HCV antibody is not proof of protective immunity. Reinfection can occur after spontaneous clearance or successful treatment. Because antibody often stays positive, a clinician generally uses HCV RNA when evaluating possible reinfection. Prevention and follow-up still matter after a previous infection has cleared.
Not always. Many people can receive treatment effective against multiple genotypes without a genotype test. Prior treatment, cirrhosis, and the proposed regimen can change that decision. Genotype testing is therefore a treatment-planning tool for selected circumstances, rather than a routine add-on for everyone having an initial HCV screen.
There is no single annual schedule for everyone. Routine adult screening, ongoing exposure, pregnancy, and monitoring of established infection follow different plans. A negative test after an old exposure does not cover future exposures. Ask what event or risk would trigger retesting, which marker is needed, and when to collect it.
Many laboratory tests can be accessed online through Ulta Lab Tests where available. First identify the question the test should answer and check its components and instructions. Arrange review with a qualified healthcare professional. Recent significant exposure, severe symptoms, and pregnancy-related concerns may require direct clinical care instead of routine self-directed ordering.
The most useful hepatitis testing plan separates infection, immunity, viral activity, and liver health. Understanding those differences helps you avoid false reassurance and unnecessary repeat testing. Explore Ulta's liver-testing guide and related testing options, then review the appropriate next step with your healthcare provider.
Originally published: February 8, 2025 | Substantively updated: September 17, 2026
Hepatitis B Core Antibody (IgM)
Hepatitis B Surface Antigen with Reflex Confirmation
Hepatitis B Core Antibody, Total
Hepatitis B Surface Antibody (Qualitative/Quantitative)
Hepatitis C AB with reflex to HCV RNA, QN, PCR
Hepatitis C Viral RNA, Quantitative, Real-Time PCR
Hepatitis C AB with HCV RNA, QN, PCR
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
